Re: Neoadjuvant PD-L1 plus CTLA-4 Blockade in Patients with Cisplatin-ineligible Operable High-risk Urothelial Carcinoma

Eur Urol. 2023 Jan;83(1):91-92. doi: 10.1016/j.eururo.2022.09.024. Epub 2022 Oct 7.

¹ Department of Surgical Oncology (Urology), Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands.
² Department of Medical Oncology, Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Molecular Carcinogenesis, Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands.
³ Department of Surgical Oncology (Urology), Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany. Electronic address: basvanrhijn@hotmail.com.

No abstract available

MeSH terms